Skip to main content

Table 2 Pathology results

From: The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy

Pathological types Uniportal VATS (%) (n = 73) Two-port VATS (%) (n = 86) Three-port VATS (%) (n = 98) P-value
Primary lung cancer 51 (69.86%) 56 (65.12%) 71 (72.45%) 0.556
Adenocarcinoma 34 (46.58%) 38 (44.19%) 52 (53.06%) 0.459
Squamous cell carcinoma 16 (21.92%) 15 (17.44%) 13 (13.27%) 0.330
Adenosquamous 0 (0%) 1 (1.16%) 1 (1.02%) 1.000
Large cell carcinoma 1 (1.37%) 0 (0%) 2 (2.04%) 0.506
Carcinoid tumors 0 (0%) 1 (1.16%) 0 (0%) 0.619
Carcinosarcoma 0 (0%) 0 (0%) 1 (1.02%) 1.000
Small cell carcinoma 0 (0%) 1 (1.16%) 2 (2.04%) 0.780
Benign disease 22 (30.14%) 30 (34.88%) 27 (27.55%) 0.556
Inflammation 3 (4.11%) 6 (6.98%) 7 (7.14%) 0.676
Pulmonary cyst 4 (5.48%) 4 (4.65%) 4 (4.08%) 0.933
Tuberculosis 4 (5.48%) 9 (10.47%) 7 (7.14%) 0.482
Pulmonary hamartoma 2 (2.74%) 3 (3.49%) 3 (3.06%) 1.000
Pulmonary fibrosis 4 (5.48%) 3 (3.49%) 1 (1.02%) 0.223
Bronchiectasis 5 (6.85%) 4 (4.65%) 4 (4.08%) 0.723
Lung sequestration 0 (0%) 0 (0%) 1 (1.02%) 1.000
Spindle cell lipoma 0 (0%) 1 (1.16%) 0 (0%) 0.619
  1. There were no significant difference in these results among the three groups (all P > 0.05)